3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
SKYX Platforms said independent director Efrat L. Greenstein Brayer died on September 26, 2026, leaving the company out of compliance with Nasdaq rules requiring a majority-independent board and an audit committee of at least three members. Nasdaq sent a cure-period letter on September 30, 2026, and the filing says there is no immediate effect on the listing, but the company cannot assure it will regain compliance in time.
Director Efrat L. Greenstein Brayer died on September 26, 2026; she sat on the audit, compensation and nominating committees.
Company notified Nasdaq on September 28, 2026 of non-compliance with Listing Rules 5605(b)(1) and 5605(c)(2)(A).
Nasdaq cure period ends at the earlier of the next annual meeting or September 26, 2027; if that meeting is before March 25, 2027, compliance is due by March 25, 2027.
The filing states there is no immediate effect on the Nasdaq listing, but no assurance was given that compliance will be regained within the cure period.
Nexalin Technology received Nasdaq confirmation on September 30, 2026 that it has regained compliance with the $1.00 minimum bid price requirement. The company still must show at least $2,500,000 in stockholders' equity by January 4, 2027, or its stock faces delisting from Nasdaq.
Nasdaq confirmed on September 30, 2026 that the bid price requirement of $1.00 per share is met
Remaining condition: stockholders' equity of at least $2,500,000 by January 4, 2027
The company says it intends to meet the equity requirement, but gives no assurance it will
American Battery Technology Company received approval from the U.S. Department of Commerce's Bureau of Industry and Security for a license to export recycled black mass, allowing sales of up to $100 million under specified terms. The license follows newly enacted federal export controls on critical battery materials, and the company says it supports current operations and its market position.
BIS approved a license allowing sales of up to $100 million of recycled black mass material
The approval follows the implementation of recently enacted federal export controls on critical battery materials
The press release, dated October 1, 2026, cites over 400% year-over-year revenue growth and references the company's fiscal year 2026 results
The filing is a Form 8-K under Item 8.01 with the press release attached as Exhibit 99.1
Gaxos.ai Inc. was notified on September 28, 2026 by Nasdaq that its common stock is not meeting the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market. The notice has no immediate effect on trading, and the company has until March 29, 2027 to regain compliance, with a possible second 180-day period and a reverse stock split under consideration.
Notice dated September 28, 2026, based on closing bid prices from August 14, 2026 to September 25, 2026
Compliance period ends March 29, 2027; stock must close at or above $1.00 for at least 10 consecutive business days
If not compliant, a second 180-day period may be available; otherwise Nasdaq would issue a delisting determination with a right to appeal to a Hearings Panel
Company may consider a reverse stock split; shares continue to trade as GXAI
Lantern Pharma received a Nasdaq notice on September 25, 2026 saying it is out of compliance with the minimum market value of listed securities requirement of $35 million over the last 30 consecutive business days. The company has until March 24, 2027 to regain compliance, or it expects Nasdaq could begin delisting proceedings from the Nasdaq Capital Market.
Nasdaq notice dated September 25, 2026 cites Listing Rule 5550(b)(2) with a $35 million minimum market value requirement
Nasdaq also said the company does not meet Listing Rules 5550(b)(1) and 5550(b)(3)
Compliance period runs 180 calendar days, ending March 24, 2027
Regaining compliance requires a market value of at least $35 million for 10 consecutive business days
BioCardia reported it has completed a revised Pre-Submission to the FDA's Center for Devices and Radiological Health for approval of its Helix Catheter, which is used for delivering therapeutic and diagnostic agents to the heart. The filing says FDA agreed in May 2026 that there are two pathways to marketing clearance and raised no concerns about Helix safety data or device performance, so the revised submission is a regulatory step toward a possible market clearance.
Revised pre-submission completed under the Q-Submission program, reported October 1, 2026.
FDA met with the company in May 2026 and said there are two pathways for Helix marketing clearance.
FDA targets an initial acceptance or refusal review within 15 calendar days and written feedback or a meeting within 70 calendar days.
The company cites clinical data from 15 clinical trials including nearly 500 patients.
Japan's Ministry of Health, Labour and Welfare approved Optune Pax for adults with unresectable locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel. The approval is based on the Phase 3 PANOVA-3 trial, which met its primary endpoint of statistically significant improvement in median overall survival, and it extends the device's regulatory approvals to another market.
Approval was first announced in a September 15, 2026 press release; the October 1, 2026 exhibit repeats it.
PANOVA-3 showed a statistically significant improvement in median overall survival for patients treated with TTFields.
Optune Pax was previously approved by the U.S. FDA in February 2026 and received a CE Mark in June 2026.
Device-related skin adverse events occurred in 76.3% of Optune Pax-treated participants; 21 (7.7%) had a Grade 3 or higher event.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.